Vivos Therapeutics, Inc. (VVOS)
- News Direct
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive shared significant news regarding the regulatory approval for Medicare reimbursement of their oral medical devices designed ...
- GlobeNewswire
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in AdultsLITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced recei
- Insider Monkey
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript March 28, 2024 Vivos Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-3.05 EPS, expectations were $-1.9. VVOS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and […]
